UNASSIGNED: Since 2003, high-risk @entity521 (HR-NB) @entity1 at our center received anti-GD2 antibody 3F8/ @entity2841 + @entity10211 - but not myeloablative therapy with autologous stem-cell transplantation (ASCT). Post-ASCT @entity1 referred from elsewhere also received 3F8/ @entity2841 + @entity10211 . We therefore accrued a study population of two groups treated during the same period and whose consolidative therapy, aside from ASCT, was identical. We analyzed @entity1 enrolled in 1st complete/very good partial remission (CR/VGPR). Their event-free survival (EFS) and @entity1349 ( @entity1349 ) were calculated from study entry. Large study size allowed robust statistical analyses of key prognosticators including @entity4180 amplification, @entity41 ( @entity41 ), @entity222 polymorphisms, and killer immunoglobulin-like receptor genotypes of natural killer cells. The 170 study @entity1 included 60 enrolled following ASCT and 110 following conventional chemotherapy. The two cohorts had similar clinical and biological features. Five-year rates for ASCT and non-ASCT @entity1 were, respectively: EFS 65% vs. 51% (p = .128), and @entity1349 76% vs. 75% (p = .975). In multivariate analysis, ASCT was not prognostic and only @entity41 -negativity after two cycles of 3F8/ @entity2841 correlated with significantly improved EFS and @entity1349 . Although a trend towards better EFS is seen with ASCT, @entity1349 is near identical. Cure rates may be similar, as close surveillance detects localized relapse and effective salvage treatments are applied. ASCT may not be needed to improve outcome when anti-GD2 immunotherapy is used for consolidation after dose-intensive conventional chemotherapy.

Lack of survival advantage with autologous stem-cell transplantation in high-risk XXXX consolidated by anti-GD2 immunotherapy and @entity10211 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity222 :: ('2212', 'Gene') :: ['FCGR2A'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'minimal residual disease'] @entity10211 :: ('MESH:D015474', 'Chemical') :: ['isotretinoin'] @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma'] @entity4180 :: ('4613', 'Gene') :: ['MYCN'] @entity2841 :: ('1437', 'Gene') :: ['GM-CSF'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity521 :: (MESH:D009447,Disease) :: ['neuroblastoma']
